RePurpose: An LLM-Assisted, Source-Traceable Drug Repurposing Tool with Retrospective Validation on Clemastine in Multiple Sclerosis
- 1Sirpi Products and Services Private Limited
Abstract
Summary Thus far, evidence for drug repurposing is contained in target-, drug-, trial-, and literature-based data sources that are challenging to synthesize for non-specialists. Here, we introduce RePurpose, a web-based tool that takes as input a topic written in plain language and returns candidate drugs built from data in Open Targets, ClinicalTrials.gov, UniProt, and PubMed. For queries in the form of a goal, RePurpose filters candidate drugs by whether they modulate all targets implicated in the goal in the corresponding direction. Every candidate has a source that contributes evidence: a structured database, a clinical trial, or a proposal from a large language model. An adjustable ranking adjusts the order of candidates from well-studied to less well-known candidate drugs. We retrospectively tested RePurpose with the trial drug clemastine, which was being considered as a remyelinating agent in multiple sclerosis (MS). RePurpose retrieved clemastine in each replicate of the mechanism-worded queries, but in no replicates of the disease-worded queries, and no structured query retrieved it without the language model enabled. Its ranked outputs reflected the evidence supporting clemastine but not later evidence of harm in progressive MS, which was reachable only through an on-demand literature search. Our results imply that RePurpose may be better at tracing evidence around a hypothesis than generating new hypotheses. Availability and Implementation RePurpose Pharma is freely accessible at https://www.repurposepharma.com/. For code and more information on the application, see: https://github.com/nayagamnitin-hub/RePurpose-Pharma.
Related
- Clemastine alleviates Parkinson’s disease pathology by activating the AMPK/mTOR pathway and enhancing autophagic flux
- Core needle biopsy washout biomarkers combined with ultrasound for preoperative axillary risk stratification in breast cancer: a retrospective nomogram study with temporal validation
- Dynamic serum chloride trajectories predict short- and long-term mortality in patients with malignancies: a retrospective cohort study with external validation
- Development and internal validation of a nomogram for predicting flexible bronchoscopy utilization in children with lobar pneumonia caused by Mycoplasma pneumoniae: a single-center retrospective cohort study
- Development and internal validation of an exploratory clinical prediction model for MRI-defined white matter injury in moderate-to-late preterm infants: a single-center retrospective study
BibTeX
@misc{nayagam2026repurpose,
title = {{RePurpose: An LLM-Assisted, Source-Traceable Drug Repurposing Tool with Retrospective Validation on Clemastine in Multiple Sclerosis}},
author = {N. Nayagam and A. Arun},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.14.759218},
url = {https://www.biorxiv.org/content/10.64898/2026.10.14.759218v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - RePurpose: An LLM-Assisted, Source-Traceable Drug Repurposing Tool with Retrospective Validation on Clemastine in Multiple Sclerosis
AU - N. Nayagam
AU - A. Arun
PY - 2026
DA - 2026/10/14
PB - bioRxiv
DO - 10.64898/2026.10.14.759218
UR - https://www.biorxiv.org/content/10.64898/2026.10.14.759218v1
AB - Summary Thus far, evidence for drug repurposing is contained in target-, drug-, trial-, and literature-based data sources that are challenging to synthesize for non-specialists. Here, we introduce RePurpose, a web-based tool that takes as input a topic written in plain language and returns candidate drugs built from data in Open Targets, ClinicalTrials.gov, UniProt, and PubMed. For queries in the form of a goal, RePurpose filters candidate drugs by whether they modulate all targets implicated in the goal in the corresponding direction. Every candidate has a source that contributes evidence: a structured database, a clinical trial, or a proposal from a large language model. An adjustable ranking adjusts the order of candidates from well-studied to less well-known candidate drugs. We retrospectively tested RePurpose with the trial drug clemastine, which was being considered as a remyelinating agent in multiple sclerosis (MS). RePurpose retrieved clemastine in each replicate of the mechanism-worded queries, but in no replicates of the disease-worded queries, and no structured query retrieved it without the language model enabled. Its ranked outputs reflected the evidence supporting clemastine but not later evidence of harm in progressive MS, which was reachable only through an on-demand literature search. Our results imply that RePurpose may be better at tracing evidence around a hypothesis than generating new hypotheses. Availability and Implementation RePurpose Pharma is freely accessible at https://www.repurposepharma.com/. For code and more information on the application, see: https://github.com/nayagamnitin-hub/RePurpose-Pharma.
ER -